CHIs Molecular Medicine Tri-Conference

Venue: Moscone North Convention Center

Location: San Francisco, California, United States

Event Date/Time: Apr 19, 2005 End Date/Time: Apr 22, 2005
Report as Spam


CHI’s Inaugural Pathway Analysis
April 20-22, 2005
San Francisco, California

Twelfth Annual Human Genome Discovery and Ninth Annual Gene Functional Analysis
Expression profiling is driving the pharmaceutical R&D process. It is being used downstream of target identification, as a biological readout for target modulation. Targets first identified through genomics then need to go through validation testing, to see if a phenotypic change occurs when a target is disregulated. These targets or pathways can be modified by using either RNAi, or the use of a chemical ligand that interacts with a target. The results are compared in order to understand a compound’s activity for on- and off- target effects. Pathway elucidation is critical to this process, in order to both identify the biochemical components in a pathway associated with disease, and the affect of a chemical entity on this pathway. This synergistic approach will help to identify ways to validate and prioritize targets, and enable us to understand the molecular mechanism of therapeutics.

CHI’s Third Annual R & D Business Strategies
April 20-22, 2005
San Francisco, California

The Pharmaceutical Strategy Series will present the Executive Track at the world renowned Molecular Medicine Tri-Conference in 2005. R&D Business Models will be one of five tracks at the 2,000-person event.
Topics to be covered include:
• In-Licensing and Out-Licensing Strategies
• Determining the Best Mix of In-Licensed verses Out-Licensed Products
• Implementing a Business Models that Best Meets a Company's Strategic Direction
• Determining the Best Mix of Late-Stage verse Early-Stage Compounds
• Best Practices for Creating Due Diligence Packages and Presenting to Big Pharma
• Creating a Successful Governance Structure
• How Pharmaceutical and Biotechnology Companies Can Differentiate Themselves as Ideal Partners

CHI’s Second Annual Mastering Medicinal Chemistry
April 20-22, 2005
San Francisco, California

As medicinal chemistry teams evolve to become more interdisciplinary, project leaders are faced with the increasingly difficult task of coordinating research involving synthetic organic chemistry, biochemistry, pharmacology, and pharmaceutical chemistry. Medicinal chemistry groups are being asked to move beyond the traditional focus on lead optimization and direct their efforts towards library design and drug discovery as well. As the research scope of a medicinal chemistry group increases, so increases the challenge of managing and training the personnel to perform that research.
The 2nd annual Mastering Medicinal Chemistry will continue to examine the medicinal chemistry field, re-define its role in drug discovery, address some of the bottlenecks, and highlight recent advances with case studies and success stories.

CHI’s Inaugural Preclinical Development
April 20-22, 2005
San Francisco, California

What model best addresses the information being pursued in the preclinical development process? How will access to representative in vivo animal models of disease and of specific pathways improve the preclinical development process and toxicity studies? Selecting appropriate assays that will enable researchers to accurately extrapolate results to humans will give considerable leverage to the projects underway. Successful translation of biomarkers from preclinical to clinical can be enabled through the use of imaging reagents, which provide insight into the activity of a compound within a physiologically complex environment, and provide a measure of predicting success in humans. By integrating information from animals and humans we can better understand function and predict drug activity and performance. The use of biomarkers in late stage drug development will improve the decision making process and success rates.

CHI’s Second Annual Clinical Molecular Diagnostics
April 20-22, 2005
San Francisco, California

Plan to take part in the 2nd annual event that last year drew from all sectors of the rapidly growing diagnostics industry to discuss key issues that will have enormous impact. How will diagnostics change the way compounds are developed and marketed? How does one choose the right biomarker? What is the most reliable route to clinical validation? Will physicians find these new diagnostics tools valuable and reliable enough to use them? How will they be introduced? What is the best business plan to move forward with this biomarker? What commercialization and regulatory issues need to be faced? Hear from key industry and government leaders as we develop a plan for turning this emerging industry into a robust economy.